CurrentCignaPolicy IP0544

Pyridostigmine 30 mg tablet — medical necessity coverage criteria for myasthenia gravis

Coverage policy governing medical necessity review and approval criteria for pyridostigmine 30 mg tablets for treatment of myasthenia gravis for Cigna-administered health benefit plans.

Policy Summary

PayerCigna

PolicyPyridostigmine 30 mg tablet — coverage criteria for myasthenia gravis

Policy CodePolicy IP0544

Change TypeRoutine review — no material changes

Effective Date4/1/2023

Next Review Date4/1/2024

Key ActionObtain prior authorization and document diagnosis of myasthenia gravis plus inability to use the 60 mg scored tablet when requesting coverage.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

12 monthsauthorization duration

30 mgtablet strength covered

4/1/2023effective date

4/1/2024next review

Coverage Criteria for Pyridostigmine 30 mg Tablet

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Provider Actions, Prior Authorization, and Documentation

Prior Authorization

Prior Authorization Requirement

Prior authorization is required per the coverage criteria; policy effective 4/1/2023 and coverage policy number IP0544.

Prior authorization required when coverage is requested for pyridostigmine 30 mg tablet

Note

Preferred product / formulation

Pyridostigmine 30 mg tablet is considered medically necessary when there is a documented inability to use pyridostigmine 60 mg scored tablet (e.g., difficulty splitting the 60 mg scored tablet). When coverage is available and medically necessary, dosage, frequency, duration of therapy, and site of care should be reasonable, clinically appropriate, and supported by evidence-based literature.

Preferred product/formulation: pyridostigmine 60 mg scored tablet is the preferred formulation when the patient can use it
30 mg tablet is preferred only when there is documented inability to use the 60 mg scored tablet

Documentation Required

Required Documentation

Documentation should include: diagnosis of myasthenia gravis; clinical rationale for using pyridostigmine (treatment history and response); documentation of inability to use pyridostigmine 60 mg scored tablet when requesting the 30 mg tablet (e.g., provider statement, patient safety concern, inability to split tablets); and pharmacy receipts or dispensing records when applicable. Receipt of sample product does not satisfy documentation requirements.

Diagnosis: myasthenia gravis documented in the medical record
Treatment history: prior use and response to pyridostigmine or reason for initial therapy
Formulation rationale: specific documentation of inability to use 60 mg scored tablet (e.g., physical limitation, swallowing/splitting issue)
Pharmacy records: dispensing records or receipt when applicable

Denial Risk

Conditions Not Covered

Use of pyridostigmine 30 mg tablet for any indication other than myasthenia gravis is considered experimental, investigational or unproven.

Not covered: indications other than myasthenia gravis

Definitions

Inability to use pyridostigmine 60 mg tablet

DefinitionDocumented inability to use the pyridostigmine 60 mg scored tablet formulation.

Justification for 30 mgWhen the 60 mg scored tablet cannot be used, pyridostigmine 30 mg tablet is considered medically necessary for treatment of myasthenia gravis.

Documentation neededMedical record must document the specific inability to use the 60 mg scored tablet (e.g., difficulty swallowing, tablet splitting not possible, or other clinically relevant reason).

ApplicabilityApplies only when coverage for pyridostigmine 30 mg is sought as an alternative to the 60 mg scored tablet formulation.